SEARCH
 

October 25 2006 / Investor

Group financial statement for the first nine months of 2006

The results for the first nine months of 2006 are highly satisfactory. Growth in operating profit and sales of 11% and 8% respectively is wholly in line with the company’s outlook. The financial outlook for 2006 is being adjusted upwards.

 

  • Sales in the first nine months of 2006 rose by just over 8% to DKK 5,038 million from DKK 4,657 million in the same period of 2005. Measured in local currencies, sales rose by just over 7%
  • Operating profit rose by 11% to DKK 1,006 million, compared with DKK 909 million in 2005
  • The operating profit margin was 20.0%, compared with 19.5% in the equivalent period of 2005
  • Net financial costs were DKK 110 million against DKK 24 million in the first nine months of 2005
  • Net profit for the period rose by 1% to DKK 671 million from DKK 664 million. Adjusted for a negative effect relating to employee share options, net profit for the period was just over 4% higher than for the same period of last year
  • Earnings per share (diluted) were DKK 13.68, an increase of 4% compared with the corresponding period of 2005
  • Free cash flow before acquisitions rose by 8% to DKK 960 million from DKK 888 million. Free cash flow after acquisitions was DKK 885 million for the first nine months of 2006
  • Return on invested capital (ROIC) rose to 20.6% from 19.8% in the same period of 2005
Outlook for 2006
Novozymes is adjusting its outlook for earnings and free cash flow upwards for 2006, assuming exchange rates remain the same. Growth in sales is expected to be approximately 8% (previously 7-9%), equivalent to approximately 8% (previously 6-8%) measured in local currencies. Operating profit is now expected to grow by approximately 10% (previously 7-9%), while growth in net profit is expected to be 5-6% (previously 5-7%). The outlook for free cash flow before acquisition is being increased to DKK 950-1,000 million (previously DKK 850-950 million). It has further been decided to increase the frame for share buy-backs for 2006 by DKK 350 million to DKK 1,350 million (previously DKK 1 billion).
 

“We are very pleased with the results,” says Steen Riisgaard, President and CEO of Novozymes. “We have had a really good third quarter with underlying growth in sales of 11%, and are standing by our outlook for sales for the year within the range originally indicated to the market. At the same time we have seen pleasing productivity improvements, enabling us to adjust the outlook for earnings upwards."

"In August 2006 Novozymes provided a bid for the Australian biotech company GroPep Ltd. as part of the strategy to leverage the company’s biotech expertise and technology platform in order to build a new business area in recombinant ingredients for the biopharmaceutical industry. I am pleased to say, that based on the satisfactory result of the independent expert’s assessment of the takeover scheme, GroPep’s Board of Directors now confirms its unanimous recommendation that shareholders vote in favour of the Share Scheme. We thereby expect the transaction to be completed by year-end.”

Download the full stock exchange announcement

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

2008 FINANCIAL CALENDAR

January 25, 2008
Group financial statement, FY 2008

March 5, 2008
Annual shareholders' meeting

April 24, 2008
Group financial statement, Q1 2008

August 14, 2008
Group financial statement, H1 2008

October 31, 2008
Group financial statement, 9M 2008

Investor Relations contacts


Camilla Kinch Jensen
Senior Director, IR

Tel. (direct): +45 4446 0852

Mobile: +45 3077 0852

ckj@novozymes.com

 
   

Tobias Bjorklund (North America)
IR Manager

Tel. (direct): +1 919 494 3483

Mobile: +1 919 649 2565
tobb@novozymes.com

Tobias Björklund
   

 

 

Press contacts


Annegrethe M. Jakobsen

Communications Manager,

Region Europe

Tel.: +45 4446 3050

Mobile: +45 3077 3050

agmj@novozymes.com

   

Johan Melchior

Press coordinator,

Coperate Communication

Tel.: +45 4446 0690

Mobile: +45 3077 0690

jmel@novozymes.com

Johan Melchior
   

 

 
Copyright © 2008 Novozymes.